Supplements That Help With Gallbladder Disease on Ozempic (Semaglutide)

Updated May 26, 2026

Image: HealthRX.com clinical illustration

Ozempic contains semaglutide, a GLP-1 receptor agonist given by weekly injection that is FDA-approved to treat type 2 diabetes in doses up to 2 mg. Semaglutide is also marketed under the brand name Wegovy for chronic weight management, which allows for a higher maximum dose. Gallbladder disease (which includes gallstones and gallbladder inflammation) has emerged as a potential complication of GLP-1 therapy, and Ozempic's prescribing information includes this as a treatment-related warning.

The direct answer

The useful question is not "which supplement prevents gallstones" but which patients have a risk profile serious enough to warrant a conversation about prescription ursodiol, since ursodiol is the only agent in this category with randomized trial support for reducing new stone formation during rapid weight loss, while vitamin C, fiber, omega-3s, and magnesium are supportive, low-risk, non-prescription measures with weaker and in several cases unverified evidence behind the specific numbers commonly attached to them. Patients losing weight quickly on semaglutide, those with a prior gallstone history, and those with a higher baseline BMI carry the most plausible reason to raise ursodiol with their prescriber; patients on a stable maintenance dose with weight loss that has plateaued have less reason to add anything beyond a normal fiber-containing diet.

Why semaglutide raises gallbladder risk

Two mechanisms are involved, and they compound each other. GLP-1 receptor agonists slow gallbladder motility, so the gallbladder empties less completely and less often after meals. Separately, rapid weight loss mobilizes stored fat and increases the amount of cholesterol the liver secretes into bile. When bile becomes supersaturated with cholesterol and the gallbladder is not contracting efficiently to clear it, cholesterol crystals have more time and more raw material to form stones.

In the STEP-1 trial of semaglutide 2.4 mg for weight management (published in the New England Journal of Medicine), gallbladder-related disorders were reported in a higher share of participants on semaglutide than on placebo over 68 weeks, consistent with the mechanism above (NEJM, Wilding et al. 2021). The SELECT cardiovascular outcomes trial of semaglutide 2.4 mg in adults with cardiovascular disease and obesity, also published in NEJM, likewise reported gallbladder-related adverse events, including a small number of cases requiring cholecystectomy (NEJM, Lincoff et al. 2023). Exact percentages differ slightly depending on how "gallbladder-related disorders" is defined in each trial's safety tables, and readers who need the precise figures for a specific dose should check the published trial and its supplementary appendix rather than relying on a single rounded number repeated online.

The FDA's Adverse Event Reporting System (FAERS) is a public database of voluntary safety reports and includes cholelithiasis reports associated with semaglutide products. FAERS counts are not a measure of incidence, since reporting is voluntary and a report does not prove the drug caused the event, but the volume of reports contributed to semaglutide's labeling including cholelithiasis under warnings and precautions. Readers who want a current count should query the FAERS public dashboard directly, since the number changes as new reports are filed and any figure quoted here would be stale by the time it is read.

Weight loss itself, independent of any drug, is an established gallstone risk factor once it crosses a certain pace, and clinicians generally consider weight loss faster than roughly 1.5 kg per week to carry meaningfully higher biliary risk than slower, more gradual loss. Patients titrating up on Ozempic often lose weight in a range that falls near or above that threshold during the first several months of treatment, which is why the early-to-mid treatment period is when gallbladder symptoms most often surface.

Ursodiol: prescription-only, the best-supported option

Ursodeoxycholic acid (ursodiol, brand names Actigall and Urso) reduces the amount of cholesterol the liver secretes into bile and helps keep cholesterol dissolved rather than crystallizing. The strongest evidence for its preventive use comes from bariatric surgery patients, a population that loses weight rapidly for reasons unrelated to GLP-1 drugs but through a biochemically similar pathway: cholesterol-supersaturated bile combined with reduced gallbladder emptying. A well-known randomized trial in post-gastric-bypass patients found that ursodiol at a maintenance dose substantially reduced new gallstone formation compared with placebo over about six months, with higher doses outperforming lower ones up to a point of diminishing returns.

No randomized trial has tested ursodiol specifically in people losing weight on semaglutide. Extrapolating from bariatric surgery data to GLP-1 therapy is a reasonable clinical judgment based on shared mechanism, not a proven equivalence, and clinicians who prescribe it this way are using it off-label for this specific indication. Ursodiol requires a prescription in the United States. Typical prophylactic dosing is discussed with a physician rather than self-selected, and side effects can include diarrhea, mild nausea, and headache. Anyone considering ursodiol should raise it with the clinician managing their Ozempic treatment rather than starting it independently.

Supportive but weaker options

Vitamin C (ascorbic acid). Vitamin C is a cofactor for the enzyme that converts cholesterol into bile acids, and higher bile acid output can reduce cholesterol saturation in bile. Observational cohort studies have reported an association between higher vitamin C intake and lower gallstone prevalence, but these are cohort and cross-sectional designs that show association, not proof of prevention, and no randomized trial has tested vitamin C specifically for gallstone prevention in people on a GLP-1 drug. A commonly used non-prescription range is 500 to 1,000 mg daily with food; doses above roughly 2,000 mg daily raise the risk of kidney stones in susceptible people, and anyone with a history of oxalate kidney stones should check with a clinician before supplementing.

Soluble fiber. Soluble fiber, particularly psyllium, binds bile acids in the intestine and forces the liver to synthesize more, which can lower cholesterol saturation in bile over time. Small controlled feeding and supplementation studies have shown favorable changes in bile composition with fiber intake in the range of roughly 10 to 15 g daily beyond baseline diet, though the sample sizes in this literature are small and the exact percentage improvements reported in various older papers should be treated as illustrative rather than precise. Fiber has the added practical benefit of addressing the constipation that semaglutide's gut-slowing effect can cause. Because psyllium also slows gastric emptying, and Ozempic already does the same, taking fiber supplements a couple of hours apart from the injection and from meals close to dosing is a reasonable precaution, along with drinking adequate water with each dose to avoid intestinal obstruction.

Omega-3 fatty acids (EPA and DHA). Fish oil may reduce cholesterol crystal formation in bile through changes in phospholipid composition. A small crossover trial in gallstone patients found that a high dose of fish oil lengthened the time it took cholesterol crystals to form in bile, and a large observational cohort of men found a modest association between higher long-chain omega-3 intake and lower rates of cholecystectomy over long-term follow-up, though the association was not consistently strong across subgroups. A commonly cited supportive dose is 2 to 4 g daily of combined EPA and DHA, which also overlaps with doses used for triglyceride management. High-dose fish oil can prolong bleeding time, so anyone on anticoagulants should discuss it with their prescriber first.

Magnesium. Some cohort data associate higher dietary magnesium intake with lower rates of cholecystectomy, plausibly through magnesium's role in insulin sensitivity, since insulin resistance is linked to higher biliary cholesterol secretion. This is an epidemiologic association, not something tested in an intervention trial for gallstone prevention. Because reduced food intake on Ozempic can also lower magnesium intake generally, correcting a magnesium shortfall (magnesium glycinate is generally better tolerated than magnesium oxide) is reasonable on its own merits, with any gallbladder benefit treated as an unproven secondary possibility.

Lecithin (phosphatidylcholine). Phosphatidylcholine helps keep cholesterol dissolved in bile, which has generated consumer interest in lecithin supplements. Oral lecithin is largely broken down in the small intestine before absorption, and no controlled human trial has shown that oral lecithin supplementation prevents gallstones. This is the weakest-supported option on this page and should not be substituted for ursodiol or the better-supported measures above.

What is established, what is plausible, and what is not established

Established: semaglutide slows gallbladder motility and rapid weight loss increases biliary cholesterol saturation; the combination raises gallstone and cholecystitis risk, which is reflected in the drug's labeling. Ursodiol reduces new gallstone formation during rapid weight loss in bariatric surgery populations, based on randomized trial evidence in that specific setting.

Plausible but unproven: that ursodiol produces a similar magnitude of benefit specifically in people losing weight on semaglutide, since no trial has tested this population directly. That vitamin C, fiber, omega-3 fatty acids, and magnesium meaningfully lower gallstone risk in GLP-1 users, based on mechanism and observational data in unrelated populations rather than direct evidence in this drug class.

Not established: that any over-the-counter supplement substitutes for ursodiol in a genuinely high-risk patient, that lecithin prevents gallstones in humans, or that a specific FAERS report count or an exact incidence percentage for any single supplement holds up without checking the current primary source, since some of the precise figures attached to this topic in secondary summaries could not be verified against a confirmed primary citation for this draft and should be checked before publication.

Warning signs that need medical evaluation, not supplements

Supplements, where supported at all, are aimed at prevention. They do not treat a gallstone or an inflamed gallbladder that has already developed. Seek prompt medical evaluation for right upper quadrant or upper abdominal pain lasting more than roughly 30 minutes, especially after fatty meals; nausea and vomiting that worsens rather than improves as treatment continues past the first couple of months; fever with abdominal pain, which can indicate acute cholecystitis; or jaundice, which can indicate a blocked bile duct. Acute cholecystitis is a surgical problem, not something a supplement regimen addresses, and same-day or urgent care is appropriate if these symptoms appear. Many patients resume semaglutide after a gallbladder is surgically removed, since a gallbladder that is no longer present cannot form new stones, though bile duct stones remain possible in a minority of patients even after cholecystectomy. Whether to pause, continue, or permanently stop Ozempic after a gallbladder event is a decision for the prescribing clinician together with a gastroenterologist or surgeon, not something to decide from a supplement list.

Decision framework: matching your risk profile to an action

Use this as a starting point for a conversation with the clinician managing your Ozempic prescription, not as a self-directed treatment plan.

Your situation	What the evidence supports	Evidence strength	What it will not do
Losing weight faster than about 1.5 kg/week, prior gallstone history, or starting BMI above 40	Ask your prescriber whether prescription ursodiol is appropriate; consider a baseline gallbladder ultrasound before starting Ozempic if you have risk factors	Ursodiol: randomized trial evidence in bariatric weight-loss patients, extrapolated off-label to GLP-1 users	Will not eliminate risk entirely; will not treat a stone or inflamed gallbladder that already exists
Losing weight at a moderate pace (roughly 0.5 to 1.5 kg/week), no prior gallstone history	Soluble fiber (psyllium) plus vitamin C with meals as a low-risk starting point; raise ursodiol with your prescriber if weight loss accelerates	Observational and small mechanistic studies; plausible but not proven in this drug class	Will not match ursodiol's demonstrated effect size in the population it has been tested in
Weight stable on a maintenance dose, no gallbladder symptoms	Maintain adequate dietary fiber, regular meals with some fat to stimulate gallbladder emptying, adequate hydration	General nutrition principles plus mechanistic reasoning	Not a substitute for medical evaluation if symptoms appear
Any new right upper quadrant pain, fever, vomiting, or jaundice	Contact your prescriber or seek urgent care; do not attempt to manage with supplements	Clinical presentation warranting evaluation, not a supplement decision	No supplement addresses an acute gallbladder event

Common questions

Frequently asked questions

How long does gallbladder disease from Ozempic last?

Gallstones that form during rapid weight loss do not dissolve on their own. They persist unless treated with dissolution therapy such as ursodiol, which works only for certain small cholesterol stones and requires months of treatment, or removed surgically. Symptom risk is generally highest during the period of most rapid weight loss and tends to fall once weight stabilizes, but existing stones remain unless treated.

Does Ozempic directly damage the gallbladder?

No. Semaglutide does not appear to cause structural damage to the gallbladder wall. It slows gallbladder motility through GLP-1 receptor activity and drives weight loss, and the combination increases the chance that bile becomes supersaturated with cholesterol. The gallbladder itself is not injured; its emptying pattern is temporarily altered.

Can ursodiol dissolve gallstones I already have?

Ursodiol can dissolve some small cholesterol gallstones over many months when taken at a dose determined by a physician, but calcified or pigment stones do not respond to it. For a patient with symptomatic stones, cholecystectomy is generally more definitive than waiting for dissolution therapy to work, and the choice between the two should be made with a physician, not decided from general information.

Is vitamin C enough on its own, without ursodiol?

Vitamin C's supportive evidence comes from observational studies showing a modest association with lower gallstone prevalence in the general population, not a randomized trial in GLP-1 users. Ursodiol has randomized trial evidence showing a much larger reduction in new stone formation, in a related but not identical population. For someone with real risk factors, vitamin C is a reasonable low-risk addition, not a substitute for a ursodiol conversation with a prescriber.

Should I take fiber supplements at the same time as my Ozempic injection?

Spacing them apart by a couple of hours is a reasonable precaution. Psyllium and other soluble fibers slow gastric emptying, and semaglutide already delays gastric motility, so taking them together may increase nausea or fullness. This is a practical tolerability point rather than a proven safety interaction.

Does slower weight loss reduce gallstone risk on Ozempic?

It is plausible, based on the general link between the pace of weight loss and gallstone risk, that a slower dose titration producing more gradual weight loss would lower biliary risk. No trial has directly tested whether adjusting semaglutide's titration schedule changes gallbladder outcomes, so this remains a reasonable inference rather than a proven strategy.

Does semaglutide cause gallbladder cancer?

There is no established link between semaglutide and gallbladder cancer. The gallbladder-related adverse events identified in clinical trials and safety databases are overwhelmingly gallstones and gallbladder inflammation, not malignancy.

Do I need a gallbladder ultrasound before starting Ozempic?

There is no universal requirement for pre-treatment imaging. A prior gallstone history, a high starting BMI, planned rapid weight loss, or a family history of gallbladder disease are reasons some clinicians choose to obtain baseline imaging. This decision should be made with the prescribing clinician based on individual risk factors.

Will removing my gallbladder stop biliary problems from Ozempic?

Cholecystectomy removes the organ where gallstones form and eliminates further cholecystitis risk from stones. It does not prevent stones that migrate into or form in the bile duct itself, which happens in a minority of people with gallstone disease. Most patients are able to continue semaglutide after gallbladder removal without recurrence of biliary symptoms.

References

Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP-1). N Engl J Med. 2021;384(11):989-1002. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232. https://www.nejm.org/doi/full/10.1056/NEJMoa2307563
U.S. Food and Drug Administration. FDA Adverse Event Reporting System (FAERS) public dashboard. https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers/fda-adverse-event-reporting-system-faers-public-dashboard

Note for editorial and medical review: several claims in the prior version of this page cited specific PubMed identifiers (ursodiol trial magnitude in bariatric patients, vitamin C and gallstone risk in the Nurses' Health Study, psyllium's effect on bile saturation, fish oil nucleation-time data, magnesium and cholecystectomy risk) that could not be independently verified against a confirmed matching paper during this revision. These claims have been described in general, hedged terms rather than linked to a specific identifier. A quotation previously attributed to a named hepatologist could not be verified and has been removed. Please verify the underlying primary literature before restoring specific citations, percentages, or the quotation.